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Previewspartly mediated by EZH2 (Figure 1B). In
addition, other more tractable targets,
such as TGF-b-FOXO signaling and
PTGS1 (a key enzyme activating the Wnt/
b-catenin pathway), were also identified
in the LIC signature shared by both SOX4
and C/EBPa leukemias (Figure 1B). TGF-
b-FOXO signaling is required for the
maintenance of LICs in chronic myeloid
leukemia (Naka et al., 2010), whereas
inhibition of b-catenin suppresses AML
stem cells induced by MLL fusions
(Wang et al., 2010; Yeung et al., 2010)
(Figure 1B). Thus, future studies in delin-
eating the molecular mechanisms and
downstream targets mediating SOX4
oncogenic function will be instrumental
for both understanding the biology of thedisease and designing better therapeutic
strategies for C/EBPa leukemia.REFERENCES
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Tumor-infiltrating macrophages typically promote angiogenesis while suppressing antitumoral T cell re-
sponses. In this issue of Cancer Cell, Klug and colleagues report that clinically-feasible, low-dose irradiation
redirects macrophage differentiation from a tumor-promoting/immunosuppressive state to one that enables
cytotoxic T cells to infiltrate tumors and kill cancer cells, rendering immunotherapy successful in mice.Macrophages are components of a
stromal-cell network that orchestrates
the angiogenic and immunosuppressive
programming of neoplastic tissues (Hana-
han and Coussens, 2012). In growing
tumors, macrophages suppress T cells
both by growth stimulation of aberrant
and dysfunctional blood vessels, which
can limit T cell extravasation, and via direct
inhibitory effects on extravasated T cells.
Macrophage depletion, or alternatively
‘‘reprogramming,’’ may present opportu-
nities to restore T cell-mediated antitumor
immunity and increase the efficacy of can-
cer immunotherapies (De Palma andLewis, 2013). In this issue of Cancer Cell,
Klug et al. (2013) show that low-dose irra-
diation (LDI) of tumors or of isolated perito-
neal macrophages followed by adoptive
transfer promotes, in both cases, a differ-
entiation switch that results in macro-
phages that attenuate angiogenesis-
driven vascular abnormalities, facilitate
T cell infiltration, and enhance the efficacy
of immunotherapy in a genetically engi-
neered mouse model (GEMM) of cancer
and xenotransplanted human melanomas
(Klug et al., 2013) (Figure 1).
In the RIP1-Tag5 GEMM of pancreatic
islet carcinogenesis, LDI (2 Gy) enhancedtumor infiltration by CD8+ T cells, the pri-
mary effectors of antitumor immune
responses. Importantly, prior LDI also
enhanced tumor infiltration and the effi-
cacy of adoptively transferred, tumor-
specific CD8+ T cells. The combination
of prior LDI with T cell transfer dramati-
cally extended the survival of tumor-
bearing mice, while either treatment alone
had equivocal effects. The extended sur-
vival is remarkable, because this GEMM
develops multiple pancreatic tumors and
dozens of angiogenic dysplasias. The
antitumor efficacy of the combined treat-
ment was associated with two importantovember 11, 2013 ª2013 Elsevier Inc. 559
Figure 1. Low Dose Irradiation Programs/Reprograms Macrophages to Promote Antitumor
Immunity
Irradiation of macrophages and/or myeloid progenitors in tumor-bearing mice, or ex vivo followed by
adoptive transfer, elicits infiltration of tumors by iNOS-expressing macrophages, which normalize the
tumor vasculature and increase the influx of CD8 T cells (either endogenous or following adoptive transfer).
The net result is tumor shrinkage and remarkable survival benefit in a mouse model of multifocal pancre-
atic neuroendocrine cancer (PanNET), illustrating successful immunotherapy of late stage solid tumors
involving a clinically feasible and likely combinable intervention.
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First, LDI and T cell transfer converted
the dysfunctional tumor blood vessels
into a more ‘‘normalized’’ vascular
network, concomitant with upregulated
expression of the leukocyte (T cell) adhe-
sion molecule VCAM1 on endothelial
cells. Such changes likely facilitate the
homing and extravasation of transferred
(as well as endogenous) CD8+ T cells to
the tumors. Second, LDI promoted tumor
infiltration of a novel class of macro-
phages expressing higher levels of induc-
ible nitric oxide synthetase (NOS2 or
iNOS) compared to macrophages found
in untreated tumors.560 Cancer Cell 24, November 11, 2013 ª20iNOS is an enzyme that converts L-argi-
nine into nitrous oxide (NO), a free radical
with diverse effects on cells. The use of a
selective iNOS inhibitor prior to LDI and
T cell transfer abrogated their antitumor
effects in RIP1-Tag5 mice. Although this
finding points to a key effector role for
iNOS in promoting the immunostimulatory
functions of macrophages, it is unclear
how LDI induces iNOS upregulation in
the macrophages or what its downstream
effector functions might be, involving the
macrophages themselves or other cells
in the tumor microenvironment including
infiltrating CD8+ T cells. The observa-
tion that macrophages upregulate iNOS13 Elsevier Inc.when treated by LDI ex vivo suggests a
cell-intrinsic effect of LDI on macro-
phages or their precursors, resulting in
induction of Nos2 transcription. It is
possible that a cellular stress response
(perhaps independent of DNA damage)
is triggered by LDI, thereby stimulating
the expression/activity of nuclear-factor
kappa-B (NF-kB) (Ahmed and Li, 2008)
or the release of inflammatory cytokines
that upregulate iNOS. Notably, the Nos2
promoter contains consensus sequences
for NF-kB.
It is conceivable that macrophage-
derived NO and infiltrating CD8+
T cells—adoptively transferred or endog-
enous—together contributed to pruning
and hence ‘‘normalizing’’ the tumor blood
vessels, enabling further influx of iNOS+
cytotoxic macrophages and T cells into
solid tumors. Notably, the abnormal tu-
mor vasculature is typically not permis-
sive for efficient T cell adhesion and trans-
migration. The molecular determinants of
this barrier involve regulatory genes,
endothelial cell receptors (e.g., endothelin
B receptor, ETBR), and proangiogenic
growth factors, some of which may be
directly or indirectly affected by NO pro-
duced by iNOS+ macrophages. Indeed,
NO has been shown to induce endothelial
cell anergy via ETBR expressed on tumor
endothelial cells (Motz and Coukos,
2011).
iNOS upregulation has been historically
associated with immunosuppressive
functions in tumor-infiltrating Gr1+ imma-
ture myeloid cells (iMCs). Indeed, accu-
mulation of iMCs in tumors and their
release of NO are known to suppress
T cell function through several mecha-
nisms, including the induction of T cell
apoptosis and the nitration or nitrosylation
of T cell receptors (Gabrilovich et al.,
2012). In contradistinction, the current
study reveals a provocative and unantici-
pated role for iNOS as an orchestrator of
effective antitumor T cell responses. The
authors note that, while LDI and T cell
transfer increased iNOS+ macrophages,
intratumoral Gr1+ iMCs were decreased.
Conversely, pharmacological inhibition
of iNOS decreased the intratumoral abun-
dance of macrophages and T cells while
increasing Gr1+ iMCs, suggesting a recip-
rocal inhibitory interplay between iNOS+
macrophages and (immunosuppressive)
Gr1+ iMCs, as is the case for macro-
phages and Gr1+ cells in other tumor
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can play diverse roles in the tumor
immune microenvironment, which may
be context and cell-type dependent. The
ostensibly dichotomous mechanisms of
iNOS/NO in supporting versus suppress-
ing CD8+ T cell activity in different
tumor/immune microenvironments thus
warrant further investigation; it remains
unclear, for example, why NO is not sup-
pressing T cells by the aforementioned
mechanisms.
Seeking to further assess the functional
importance of macrophages to the LDI
phenotype, macrophages were depleted
with clodronate liposomes prior to LDI
and adoptive transfer of T cells. Macro-
phage depletion impaired T cell recruit-
ment into the tumors and eliminated their
antitumoral effects. Conversely, as noted
above, the transfer of ex vivo irradiated
macrophages into nonirradiated RIP1-
Tag5 mice was sufficient to elicit vascular
normalization and T cell recruitment and
tumor control by the transferred CD8+
T cells. Thus, macrophage precursors
(and perhaps mature macrophages) pre-
conditioned by LDI can be programmed/
reprogrammed into macrophages that
modify the tumor microenvironment to
unleash the cytotoxic functions of CD8+
T cells.
Klug et al. (2013) did not compare LDI
with high-dose tumor irradiation (HDI;
10–25 Gy in single or fractionated doses),
which is known to trigger a reparative
response involving macrophages that
facilitates tumor revascularization and
regrowth. Interestingly, HDI of mouse
tumors appears to programmacrophages
toward a ‘‘wound-healing’’ and protu-
moral phenotype, and macrophage
depletion from HDI-treated tumors effec-
tively limits post-therapy tumor relapse
(Russell and Brown, 2013). An earlier
study showed that HDI can also upregu-
late iNOS in macrophages and that HDI-
irradiated iNOS+ macrophages enhanced
tumor growth in mice (Tsai et al., 2007),suggesting that a distinct mechanism
is involved in the immunostimulatory,
tumor-antagonizing phenotype of LDI-
programmed macrophages.
Differential macrophage activation in
tumors can elicit either pro- or antitumoral
(immune) responses (De Palma and
Lewis, 2013). The study by Klug et al.
(2013) supports the emerging concept
that macrophage programming/reprog-
ramming—as opposed to a broad-brush
macrophage depletion approach—may
present an attractive means to improve
the efficacy of anticancer therapies. This
concept is supported by a number of pre-
clinical and clinical studies highlighting
the therapeutic benefits of targeting mac-
rophages with immunomodulatory anti-
bodies, such as anti-CD40 or anti-CD47,
which are capable of reprogramming
macrophages toward a tumoricidal and
immunostimulatory phenotype (De Palma
and Lewis, 2013; Tseng et al., 2013).
The potential clinical applicability of
LDI-mediated programming of macro-
phages is supported here by a retro-
spective analysis of human pancreatic
adenocarcinomas previously treated by
LDI in a neoadjuvant setting. In these
tumors, LDI significantly increased the
proportion of iNOS+ macrophages and
CD8+ T cells, and decreased the average
size of the tumor blood vessels, possibly
reflecting vascular normalization. More-
over, experiments employing an ortho-
topic xenotransplant mouse model of
human melanoma in which tumor-bearing
mice were treated with LDI and adoptive
transfer of tumor-specific T cells largely
recapitulated the findings in RIP1-Tag5
mice. Collectively, the results should
incentivize discussion of clinical trials to
further evaluate the potential of LDI,
perhaps starting from dose-escalation
studies that directly compare LDI with
HDI in terms of effects on macrophages,
the vasculature, and T cell infiltration
and, in particular, to establish the optimal
‘‘low dose’’ to program macrophage dif-Cancer Cell 24, Nferentiation and enhance T cell infiltration
while limiting toxicity. Importantly, LDI
therapy should be readily deliverable in
traditional radiation oncology facilities
worldwide. As such, the likely tolerability
and noninvasive modality of LDI make it
an attractive candidate for combinations
with novel immunotherapeutic agents,
such as adoptive transfer of chimeric
antigen receptor- or TCR-engineered
T cells or treatment with immune check-
point blockers (e.g., anti-PD1/PDL1
and/or anti-CTLA4), tumor vaccines, or
immunogenic chemotherapy. If validated,
LDI in such combinations could prove
to be an important new interventional
agent in the exciting frontier of tumor
immunotherapy.REFERENCES
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